Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | PLD1 | Q13393 | 4/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.55 |
| ▸ | PLD2 | O14939 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636659 | 0.92 | OPRM1 (0.53) | HSD11B1CHRM1HTR1AADRA2ADRD2 | |
| SCHEMBL29198147 | 0.88 | CHRM1 (0.53) | HSD11B1CHRM1CCR5OPRM1 | |
| SCHEMBL14146573 | 0.87 | CCR5 (0.51) | HSD11B1CHRM1HTR1AADRA2ADRD2 | |
| SCHEMBL28706708 | 0.87 | CCR5 (0.51) | HSD11B1CHRM1DRD2PLD1CCR5 | |
| SCHEMBL30870565 | 0.87 | HSD11B1 (0.60) | HSD11B1CHRM1DRD2PLD1CCR5 | |
| SCHEMBL8047936 | 0.87 | HSD11B1 (0.60) | HSD11B1CHRM1DRD2PLD1CCR5 | |
| SCHEMBL19358792 | 0.87 | CCR5 (0.54) | HSD11B1CHRM1HTR1ACCR5OPRM1 | |
| SCHEMBL4443186 | 0.86 | HSD11B1 (0.52) | HSD11B1CHRM1PLD1CCR5PLD2 | |
| SCHEMBL22587911 | 0.86 | HSD11B1 (0.56) | HSD11B1CHRM1CCR5OPRM1 | |
| SCHEMBL4434708 | 0.86 | CCR5 (0.53) | HSD11B1CHRM1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| CN-113924296-B | 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社 钟根堂 | 2024-09-17 | — | — | CN | disclosed |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4353713-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Kinki University (JP) | 2024-04-17 | — | — | EP | disclosed |
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| EP-3976604-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2022-04-06 | — | — | EP | disclosed |
| CN-113924296-A | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2022-01-11 | — | — | CN | disclosed |
| WO-2020240492-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020240492-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-12-03 | — | — | WO | disclosed |
| CN-107001332-B | Piperidine derivatives | 豪夫迈·罗氏有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| WO-2016087352-A1 | NOVEL PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| US-7388020-B2 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2008-06-17 | — | — | US | disclosed |
| US-20040116435-A1 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| EP-1373248-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074763-A9 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002074763-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | HSD11B1 638/4885CHRM1 65/4885HTR1A 123/4885 |
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC6, HDAC1, HDAC2 | HSD11B1 84/4885CHRM1 3242/4885HTR1A 1529/4885 |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1G, CACNA1I, CACNA1H | HSD11B1 2831/4885CHRM1 187/4885HTR1A 1280/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | HSD11B1 638/4885CHRM1 65/4885HTR1A 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.